01/05/2017 Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes Icon check
01/04/2017 Adocia announces its financial calendar for 2017 Icon check
12/16/2016 Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro Icon check
11/10/2016 Adocia to Participate in Upcoming Investor Conferences Icon check
11/07/2016 Adocia receives the 1st prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ prize as part of the 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes Icon check
10/27/2016 Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Icon check
10/12/2016 Adocia announces third quarter 2016 financial results Icon check
09/22/2016 Adocia received the EY Global Company Award for the Auvergne Rhône-Alpes region Icon check
09/20/2016 Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes Icon check
09/19/2016 Adocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET) Icon check
09/15/2016 BioChaperone® Combo, a co-formulation of lispro and glargine, demonstrates both prandial and basal insulin time-action profiles in a single injection in type 2 diabetes, Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)
09/15/2016 “BioChaperone® Combo (BC Combo) reduces post-prandial glucose in type 1 diabetes compared to conventional lispro mix 75/25 (LMx)” (Poster 836), presented by Dr. S. Bruce, 52nd European Association for the Study of Diabetes (EASD) Annual Meeting, 12–16 September 2016, Munich (Germany)
09/08/2016 Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting Icon check
09/07/2016 Adocia announces new BioChaperone program combining a basal insulin and GLP-1s Icon check
08/25/2016 Adocia announces topline results of Indian Phase 3 trial of BioChaperone PDGF for diabetic foot ulcer Icon check
07/20/2016 Adocia presents first half 2016 financial results Icon check
07/05/2016 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Icon check
06/11/2016 “A Pilot Bioequivalence (BE) Study of Ultra-Rapid Concentrated BioChaperone® Lispro (BCLIS) U200 to BCLIS U100”, (Abstract 2242-PUB), presented by Dr. Grit Anderson, 76th Scientific Sessions of the American Diabetes Association, 10-14 June 2016, New Orleans, LO (USA)
06/10/2016 “Pharmacodynamic (PD) Profile of BioChaperone® Combo (BC Combo), a New Combination of Rapid-Acting and Long-Acting Insulin, in Subjects with Type 2 Diabetes Mellitus (T2DM)” (Poster 942), presented by Dr. Simon Bruce, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)
06/08/2016 Adocia reinforces its focus on diabetes with the launch of a new project: BioChaperone Glucagon Icon check
06/06/2016 Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions Icon check
06/02/2016 Adocia to Present at the Jefferies 2016 Global Healthcare Conference Icon check
05/31/2016 Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects Icon check
05/13/2016 Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris Icon check
05/03/2016 Adocia strengthens its BioChaperone Combo patent portfolio Icon check
04/27/2016 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes Icon check
04/14/2016 Adocia announces first quarter 2016 results Icon check
04/11/2016 Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Icon check
04/11/2016 Adocia announces the release of its Reference Document, for the year 2015 Icon check
03/25/2016 ADOCIA confirms its eligibility for the PEA – PME Icon check
03/21/2016 Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board Icon check
03/16/2016 Annual Financial Results 2015 Icon check
03/14/2016 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Icon check
02/16/2016 ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015 Icon check
02/04/2016 Adocia to Present at the 2016 Leerink Global Healthcare Conference Icon check
01/29/2016 Adocia and Lilly initiate Phase 1b study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects Icon check
01/08/2016 Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets Icon check
12/16/2015 Adocia announces its financial calendar for 2016 Icon check
12/15/2015 Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 Icon check
12/11/2015 Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100 Icon check
11/25/2015 Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes Icon check
11/19/2015 Adocia receives the Deloitte In Extenso Technology Fast 50 Prize in the “Listed Company” category for the Grand Rhône-Alpes region Icon check
11/04/2015 Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 diabetes Icon check
10/13/2015 ADOCIA Reports Third Quarter 2015 Financial Results Icon check
10/06/2015 Adocia and Lilly initiate a Phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy Icon check
10/05/2015 Adocia to hold an extraordinary shareholders’ meeting on November 12, 2015 in Lyon Icon check
09/30/2015 Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes Icon check
09/17/2015 ADOCIA: additional contribution to the liquidity agreement Icon check
08/27/2015 Adocia and Lilly initiate new Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Icon check
07/21/2015 Adocia presents financial results for the first half of 2015 highlighting strong growth Icon check
07/10/2015 Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo
06/26/2015 Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Icon check
06/15/2015 Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices Icon check
06/05/2015 “Ultra-Rapid BioChaperone® Insulin Lispro (BC LIS): Linear Dose-Response and Faster Absorption than Insulin Lispro (LIS)” (Poster 979), presented by Dr. Grit Anderson, 75th Scientific Sessions of the American Diabetes Association, 5-9 June 2015, Boston, MA (USA)
05/28/2015 Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015 Icon check
05/26/2015 Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA) Icon check
05/04/2015 Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014 Icon check
04/29/2015 Adocia is now integrated into the EnterNext Tech 40 Index Icon check
04/20/2015 Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon Icon check
04/14/2015 Adocia announces first quarter 2015 results Icon check
Join our mailing list. Subscribe